Panacea Biotec on Tuesday said that it has entered into an agreement to sell its formulation business in India and Nepal to Mankind Pharma for Rs. 1908 crore.

In FY21, the domestic business assets generated a turnover of Rs 219.85 crore, which is 35.19% of the company's revenue on a consolidated basis. Panacea reported revenues of Rs 625 crore in FY21.

Panacea said it expects to complete the transaction by the end of this year.

Panacea domestic business gets most of its revenues from therapeutic segments such as organ transplantation, diabetes, pain, cough, and cold, and gastroenterology.

Click for more articles on Panacea Biotec

The company top selling brands are:

- Pangraf (tacrolimus),
- Alphadol (alfacalcidol),
- Cilamin (penicillamine)
- Livoluk Fibre (lactulose in combination with ispaghula)

Click for more on Mankind Pharma

These brands were ranked number one, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were amongst the top 5 brands in their respective markets.

Panacea has been struggling with high debt. The company has a net debt of Rs 984 crore on a consolidated basis with a debt equity ratio of 4.53.
https://thehealthmaster.com/2022/02/02/panacea-sells-domestic-formulation-assets-to-mankind-pharma/